Adam Kaplin

Adam Kaplin, M.D., Ph.D.,  graduated from Yale University before receiving his M.D. and Ph.D. from the Johns Hopkins University School of Medicine. Dr. Kaplin has a joint appointment as a clinician-researcher in the departments of psychiatry and neurology at Johns Hopkins, where his research focuses on immune-mediated mechanisms of depression and cognitive impairment in CNS autoimmune diseases. He is the principle psychiatric consultant to the Johns Hopkins Multiple Sclerosis and Transverse Myelitis Centers.

Dr. Kaplin is the chairman of the scientific advisory board for the Montel Williams MS Foundation. He is also a medical advisor to the Cody Unser First Step Foundation (CUFSF), the Transverse Myelitis Association (TMA), the Johns Hopkins Project RESTORE, and the Nancy Davis MS Foundation.

Dr. Kaplin is the inventor and co-developer of www.mood247.com, a mood-tracking technology. He is also the CEO and president of Altammune, a startup biotechnology company specializing in developing aggressive new therapies to put autoimmune diseases into long-term remission.